[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355652-105":59,"doc-detail-355652-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-landscape-and-clinical-translation-of-dna-damage-response-alterations-in-solid-tumors-a-pan-cancer-perspective-on-precision-oncology-2026","Molecular landscape and clinical translation of DNA damage response alterations in solid tumors - A pan-cancer perspective on precision oncology - 2026","","DNA damage response (DDR) pathways are essential for maintaining genomic integrity, and growing pan-cancer evidence shows that DDR network alterations act as widespread drivers of tumor initiation, progression, and therapeutic vulnerability. This review integrates biological mechanisms and clinical implications of DDR defects across solid tumors. It explains how major DDR pathway disruptions cause genomic instability and mutational heterogeneity, links DDR deficiency to the tumor immune microenvironment, and evaluates synthetic-lethality-based targeted strategies, especially PARP inhibitors. It connects these insights to clinical translation through genetic risk assessment, biomarker development, and precision therapeutic decisions, aiming to improve targeted and combinatorial treatments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-landscape-and-clinical-translation-of-dna-damage-response-alterations-in-solid-tumors-a-pan-cancer-perspective-on-precision-oncology-2026/355652/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-landscape-and-clinical-translation-of-dna-damage-response-alterations-in-solid-tumors-a-pan-cancer-perspective-on-precision-oncology-2026/355652.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role do DNA damage response (DDR) pathways play in cancer development?","Question",{"text":112,"@type":113},"DDR pathways maintain genomic integrity by coordinating lesion detection, cell-cycle checkpoints, and DNA repair. Defects in DDR genes can drive genomic instability, supporting tumor initiation, progression, and therapeutic resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do DDR defects create therapeutic opportunities through synthetic lethality?",{"text":117,"@type":113},"The discovery of synthetic lethality enables targeted therapy, exemplified by the clinical success of PARP inhibitors in homologous recombination deficiency (HRD) tumors. DDR deficiencies can therefore guide treatment selection and vulnerability exploitation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does this review connect DDR alterations to clinical translation and precision oncology?",{"text":121,"@type":113},"It links mechanistic DDR pathway disruptions to clinical needs by discussing genetic risk assessment, biomarker development, and precision therapeutic decision-making. It also considers how DDR deficiencies may influence the tumor immune microenvironment and immunotherapy response.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355652,1790217157,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Neoplasia 77 (2026) 101315  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology |  |  | |\n| --- | --- | --- | --- |\n| Haixia Zhua,1, Jingjing Shao a,1, Yaxuan Wang a,1, Chunyan Gub,*, Jibin Liu c,* a Cancer Research Center Nantong, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, China b Department of Pathology, Nantong Third People's Hospital & Affiliated Nantong Hospital 3 of Nantong University, Nantong, China\u003Cbr>c Institute of oncology, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, China |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>DNA damage response Genomic instability Gene mutations Synthetic lethality PARP inhibitors |  | DNA damage response (DDR) pathways are essential for maintaining genomic integrity. Accumulating pancancer evidence, however, reveals that alterations within these networks act as widespread drivers of tumor initiation, progression, and therapeutic vulnerability. This review synthesizes the biological mechanisms and clinical implications of DDR defects across solid tumors. We first detail how the disruption of major DDR pathways leads to profound genomic instability and characteristic mutational heterogeneity. Building on this mechanistic foundation, we evaluate the interaction between DDR deficiencies and the tumor immune microenvironment to highlight emerging opportunities for immunotherapy. We also critically examine recent advancesin targeted treatment paradigms based on synthetic lethality, focusing particularly on the evolving clinical landscape of PARP inhibitors. Finally, we link these biological insights directly to clinical practice by discussing genetic risk assessment, biomarker development, and precision therapeutic decision-making. Ultimately, a deeper understanding of these alterations is essential to develop more effective targeted and combinatorial therapies for patients with DDR-deficient malignancies. |  |\n\nIntroduction  \nMaintenance of genomic integrity is essential for normal cellular function and organismal survival [1]. The DNA damage response (DDR) network comprises a complex system of signaling pathways responsible for detecting DNA lesions, coordinating cell cycle checkpoints, and facilitating DNA repair (Fig. 1). These pathways involve multiple specialized repair mechanisms, including homologous recombination (HR), non-homologous end joining (NHEJ), and mismatch repair (MMR). Notably, base excision repair (BER) plays a central role in processing non-bulky lesions induced by endogenous metabolic stressors, such as reactive oxygen species (ROS). Collectively, these coordinated mechanisms protect the genome from a diverse array of endogenous and exogenous damage [2]. Defects in DDR genes can lead to the accumulation of genomic instability, a hallmark of cancer development, and contribute to tumor initiation, progression, and therapeutic resistance [3]. Recent advances in high-throughput sequencing technologies have revealed that alterations in DDR genes are prevalent across a wide spectrum of human malignancies [4–10].  \nMutations in key DDR components such as BRCA1, BRCA2, ATM, ATR, PALB2, and mismatch repair genes not only influence cancer susceptibility but also affect tumor behavior and response to treatment. Importantly, the discovery of synthetic lethality has opened new avenues for targeted therapy, exemplified by the clinical success of poly (ADP-ribose) polymerase (PARP) inhibitors in tumors with homologous recombination deficiency (HRD) [1]. In addition to guiding targeted therapies, DDR alterations are increasingly recognized as potential biomarkers for patient stratifica","cbCaip882MqXc5o4","https://ap.wps.com/l/cbCaip882MqXc5o4","pdf",8572897,"English","# Introduction\n## Molecular landscape and clinical translation of DDR alterations across solid tumors\n## Maintenance of genomic integrity and DDR network overview\n## DDR gene mutations, synthetic lethality, and biomarker potential\n# Epidemiological characteristics and molecular profiles of DDR mutations across different tumors\n## Pan-cancer prevalence and distribution of DDR alterations","[{\"question\":\"What role do DNA damage response (DDR) pathways play in cancer development?\",\"answer\":\"DDR pathways maintain genomic integrity by coordinating lesion detection, cell-cycle checkpoints, and DNA repair. Defects in DDR genes can drive genomic instability, supporting tumor initiation, progression, and therapeutic resistance.\"},{\"question\":\"How do DDR defects create therapeutic opportunities through synthetic lethality?\",\"answer\":\"The discovery of synthetic lethality enables targeted therapy, exemplified by the clinical success of PARP inhibitors in homologous recombination deficiency (HRD) tumors. DDR deficiencies can therefore guide treatment selection and vulnerability exploitation.\"},{\"question\":\"How does this review connect DDR alterations to clinical translation and precision oncology?\",\"answer\":\"It links mechanistic DDR pathway disruptions to clinical needs by discussing genetic risk assessment, biomarker development, and precision therapeutic decision-making. It also considers how DDR deficiencies may influence the tumor immune microenvironment and immunotherapy response.\"}]","Molecular landscape and clinical translation of DNA damage response alterations in solid tumors - A pan-cancer perspective on precision oncology - 2026 | PDF",1790120361,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eae91351ef640e7f518dafb8ffc4a865.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c50aa664e8b70db4b35b6b1f9dcc033.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9bb6fd8c5edca091d8b2cc69df7060d6.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56153cab7c617b3320c6e0f924f90700.webp",980,1306]